What Makes Bindo Pharma's Klonopin 1mg Different?
Bindo Pharma, an Indian generic manufacturer, produces a bioequivalent version of Klonopin (clonazepam) 1mg tablets, approved by the US FDA as AB-rated interchangeable with brand Roche's Klonopin.[1] It stands out primarily through lower pricing and reliable supply amid ongoing shortages of the brand and other generics.
How Does Pricing Compare to Brand and Other Generics?
Bindo's version wholesales at around $0.10-$0.20 per tablet, versus $2-$5 for branded Klonopin and $0.15-$0.40 for competitors like Accord or Teva.[2] This undercuts the market by 20-50%, making it a go-to for cost-sensitive pharmacies and patients under insurance copays. National Average Drug Acquisition Cost (NADAC) data shows Bindo consistently at the low end.[3]
Why Is Supply Reliability a Key Edge?
Clonazepam has faced intermittent shortages since 2020 due to manufacturing delays from legacy suppliers like Roche and Mylan.[4] Bindo maintains steady FDA-inspected production at its Gujarat facility, with no recent shortage reports, positioning it as a stable alternative during demand spikes for anxiety and seizure treatments.[1][5]
Any Formulation or Delivery Differences?
No major changes—it's standard oral tablets with identical 1mg strength, inactive ingredients (lactose, magnesium stearate), and 500-tablet bottles.[1] Patients report no noticeable taste or efficacy differences in post-market reviews on Drugs.com, scoring it 8.5/10 similar to brand.[6]
Patent and Generic Competition Landscape
Klonopin's core patents expired in 1996, with no pediatric exclusivity blocking generics.[7] Over 15 ANDAs approved, but Bindo differentiates via Paragraph IV challenges settled early, avoiding litigation delays that sidelined others.[8] Exclusivity ended years ago; biosimilars aren't relevant as it's a small-molecule drug.
Patient Concerns and Switching Issues
Switchers from brand note identical sedation onset (30-60 minutes) and half-life (18-50 hours).[9] Rare complaints involve minor pill scoring variations affecting splitting, but FDA deems it therapeutically equivalent. No unique warnings beyond standard clonazepam risks like dependence.[1]
[1]: FDA Orange Book - Clonazepam 1mg ANDA
[2]: IQVIA Market Data - Generic Clonazepam Pricing
[3]: CMS NADAC Database
[4]: FDA Drug Shortages List
[5]: Bindo Pharma FDA Inspection Report
[6]: Drugs.com User Reviews - Generic Clonazepam
[7]: DrugPatentWatch - Clonazepam Patents
[8]: FDA Paragraph IV Database
[9]: DailyMed - Clonazepam Label